## ATTORNEY'S DOCKET NUMBER: 2003946-0080 (FP04-0096-US)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Yamamoto, et al.	Examiner:	PAGONAKIS, Anna
Serial No.:	10/797,903	Group Art Unit:	1609
Filing Date:	March 10, 2004		
Title:	C-KIT KINASE INHIBITOR		

## VIA EFS WEB FILING – WWW.USPTO.GOV

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

In response to the Restriction Requirement mailed July 17, 2007, in the above-referenced case, Applicant elects *Group II*, directed to claims 12-17, drawn to method of treatment using a c-Kit kinase inhibitor, classified in class 514, subclass 183. Applicant further selects *small cell lung cancer* as the species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Claims 12-15 and 17 of Group II read on the elected species.

The deadline for filing a response to the Restriction Requirement mailed July 17, 2007 is August 17, 2007. The filing of this response on August 15, 2007 is therefore timely. Please charge any fees that may be associated with this matter, or credit any overpayments, to our Deposit Account No.: 03-1721.

Respectfully submitted,

/Charles E. Lyon, D.Phil./ Charles E. Lyon, D.Phil. Registration No. 56,630

Dated: August 15, 2007

Choate, Hall & Stewart LLP Two International Place Boston, MA 02110 (617) 248-5000